Mendus Q2 FY26 net loss narrows to SEK 21.38 million

PUBT · 2d ago
Mendus Q2 FY26 net loss narrows to SEK 21.38 million
  • Mendus AB (publ) posted a Q2 net loss of SEK 21.38 million; loss per share narrowed to SEK 0.34.
  • Operating loss improved to SEK 20.5 million; no revenue was recognized.
  • Cash totaled SEK 59.88 million; shareholders’ equity was SEK 545.29 million, leaving an 88% equity ratio.
  • VITAL-CML trial secured regulatory approvals, launched clinical development in CML, completed first-stage enrollment, with an initial readout expected in H2 2026.
  • CEO Erik Manting highlighted momentum across myeloid blood cancers, with DIVA expected to start in H2 2026 and VITAL-TFR2 targeted for Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mendus AB (publ) published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.